Follow these tips to avoid the overuse of edit checks and build better studies.
It is up to pharmaceutical companies sponsoring clinical trials in the EU to have complete control of their supply chain. Understanding recent changes to the EU GDP guidelines can help achieve this as they now offer a more comprehensive guidance for temperature management during storage and transportation.
Identifying the optimal formulation and dose form which shows an increase more than 20 times in the oral bioavailability of Salmon Calcitonin.
While Andexanet Alfa’s Breakthrough Designation added additional stress to the supply chain, Portola and Sherpa navigated these issues by devising fast, flexible and responsive approaches to supply chain management.
For methodological reasons, patient-centric study engagement and retention solutions appropriate for clinical trials may not always be suitable for real-world studies.
In the first annual Patient Adherence Influence Report, Adheris Health and inVentiv Health Consulting set out to understand the most influential factors driving patient adherence or non-adherence and to answer the question: Will the patient cross the finish line at the retail pharmacy, or will he or she walk away?
See how this service can benefit you with shorter lead time, less waste, less stock out risk and no booklet labels.
In this webinar, INC Research/inVentiv Health experts discuss the factors that sponsors must take into account as they design and execute clinical trials in this space, beginning with a review of the immunotherapy landscape.
Hear insights from Sam Herbert, president of World Courier, regarding how the evolution of the supply chain in traditional small and large molecules is a handoff from clinical partners into commercial partners.
The number of oncology clinical trials has increased exponentially in recent years, putting ever more pressure on increasing clinical trial efficiency by reducing costs and timelines. Patient recruitment swallows 40% of trial costs, yet only 10–17% of studies enroll on time and approximately 11% of sites in any given study fail to enroll a single patient.
Do you face the challenge of recruiting and retaining rare disease patients for orphan drug clinical trials? Now, discover how you can boost participation, enhance outcomes and speed drug development in this competitive market.
Developing informed consent content requires a lot of back and forth communication between multiple stakeholders - an inefficient, slow process with a history of allowing unapproved or out-of-date consents to be accidentally deployed to sites. Electronic Informed Consent (eConsent) offers a streamlined, collaborative process that promotes faster content development, approval and deployment on one platform, guaranteeing that only the most current and approved consent version is used each time.
MedNet Solutions provides the highest quality study build training and support possible to help you succeed and to ensure you get the most out of your technology investment.
At MedNet Solutions, we are dedicated to providing the highest quality training and supportive services possible to help our customers succeed and to ensure they get the most out of thier technology.